leflunomide has been researched along with Cancer of Prostate in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozturk, S | 1 |
| Mathur, D | 1 |
| Zhou, RW | 1 |
| Mulholland, D | 1 |
| Parsons, R | 1 |
| Hail, N | 1 |
| Chen, P | 1 |
| Bushman, LR | 1 |
| Shawver, LK | 1 |
| Schwartz, DP | 1 |
| Mann, E | 1 |
| Chen, H | 1 |
| Tsai, J | 1 |
| Chu, L | 1 |
| Taylorson, L | 1 |
| Longhi, M | 1 |
| Meredith, S | 1 |
| Germain, L | 1 |
| Jacobs, JS | 1 |
| Tang, C | 1 |
| Ullrich, A | 1 |
| Berens, ME | 1 |
| Hersh, E | 1 |
| McMahon, G | 1 |
| Hirth, KP | 1 |
| Powell, TJ | 1 |
| Ko, YJ | 1 |
| Small, EJ | 1 |
| Kabbinavar, F | 1 |
| Chachoua, A | 1 |
| Taneja, S | 1 |
| Reese, D | 1 |
| DePaoli, A | 1 |
| Hannah, A | 1 |
| Balk, SP | 1 |
| Bubley, GJ | 1 |
| George, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma[NCT02303899] | Phase 2 | 22 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for leflunomide and Cancer of Prostate
| Article | Year |
|---|---|
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mes | 2001 |
1 trial available for leflunomide and Cancer of Prostate
| Article | Year |
|---|---|
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Immunohistochemistry; Isoxazoles; Leflunomid | 2001 |
3 other studies available for leflunomide and Cancer of Prostate
| Article | Year |
|---|---|
Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer.
Topics: Animals; Cell Line; Cell Line, Tumor; Humans; Immunosuppressive Agents; Leflunomide; Male; Mice; Mic | 2020 |
Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caspases; Cell Line, Transformed; Cytochromes c; Dos | 2010 |
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Topics: 3T3 Cells; Animals; Brain Neoplasms; Cell Survival; Epidermal Growth Factor; Female; Glioma; Growth | 1997 |